Verrica Pharmaceuticals Inc.
VRCA
$0.4891
$0.02264.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -14.31% | -75.92% | -271.06% | -257.15% | -173.59% |
| Total Depreciation and Amortization | 51.79% | 50.37% | 36.60% | 27.82% | 16.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.28% | -3.53% | 218.02% | 202.21% | 156.15% |
| Change in Net Operating Assets | -79.44% | 140.06% | -108.36% | 1,014.93% | 647.72% |
| Cash from Operations | -57.94% | -104.55% | -429.73% | -261.97% | -106.85% |
| Capital Expenditure | 92.54% | -26.37% | -42.25% | -13.96% | -19.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 94.75% | -103.84% | -103.46% | -103.19% | -100.67% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -3,917.39% | -- | 99.19% | 99.59% | 99.95% |
| Issuance of Common Stock | 31.29% | -99.49% | -99.73% | -99.99% | 12.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -547.73% | -654.34% | -958.93% | -2,246.43% | -935.29% |
| Cash from Financing | -49.16% | -102.32% | 220.09% | 222.25% | 539.91% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -165.82% | -218.35% | -339.03% | -215.38% | 90.45% |